During the corresponding time, Exact Sciences Corporation recorded a revenue increase by 23.12 % year on year, sequentially revenue grew by 3.35 %. While revenue at the Exact Sciences Corporation's corporate clients
Exact Sciences's Comment on Sales, Marketing and Customers
Exact Sciences Corporation develops and provides cancer screening and diagnostic tests aimed at earlier cancer detection and treatment guidance. Its product portfolio includes Cologuard, Oncotype DX, Cologuard Plus, Oncodetect, and Cancerguard tests. Oncodetect has received Medicare reimbursement for patients with stage II, III, and resectable stage IV colorectal cancer. The company has an exclusive license agreement with Freenome Holdings, Inc. for blood-based colorectal cancer screening. Customers and market participants associated with Exact Sciences include Abbott Laboratories, Badger Merger Sub I, Inc., and Freenome Holdings, Inc.
In a significant advancement for colorectal cancer (CRC) patients, Exact Sciences Corp., a leading player in cancer diagnostics, recently announced that its Oncodetect molecular residual disease (MRD) test will now be covered by Medicare. This decision, made through the Centers for Medicare and Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX), marks a crucial development for patients with stage II, III, and resectable stage IV colorectal cancer, facilitating monitoring for recurrence and effectiveness of adjuvant therapies.The Oncodetect test is designed to detect minute traces of cancerous cells post-treatment, allowing physicians to assess whether patients remain disease-free or face t...
MADISON, Wis. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, continues to push the boundaries in cancer early detection and diagnostics, as evidenced by two significant recent announcements. The company recently enrolled the first patient in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) study, while also gearing up to present a series of impactful data at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. First Enrollment in MCED Falcon Registry RWE Study Exact Sciences made a significant leap in the field of cancer detection with the initiation of their Multi-Cancer Early Detection (MCED) Falcon ...
MADISON, Wisconsin Exact Sciences Corp. (Nasdaq: EXAS), a pioneering provider of cancer screening and diagnostic tests, continues to solidify its leadership in the field of oncology. The company is set to showcase 10 abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31 to June 4, 2024, in Chicago, Illinois. This event will spotlight the breadth and depth of Exact Sciences portfolio in early cancer detection, diagnosis, and treatment improvement. The ASCO Annual Meeting is one of the most anticipated conferences in the oncology community, serving as a global stage for groundbreaking research and cutting-edge technologies in cancer care. Exact Sciences presen...
Exact Sciences Corp. (Nasdaq: EXAS), a front-runner in the field of cancer diagnostics and screening, is set to assert its dominance in early cancer detection with a robust presentation at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). Scheduled to take place from May 31 to June 4, 2024, in Chicago, this event will serve as a premier platform for Exact Sciences to showcase ten insightful abstracts that underscore its extensive product portfolio. Enhancing Cancer Detection CapabilitiesExact Sciences has been a stalwart in developing diagnostic tools aimed at early cancer detection and improving patient health outcomes. The company s innovative approach is demonstrated through...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, recently showcased its continued leadership and groundbreaking advancements in early cancer diagnosis at this year s American Society of Clinical Oncology (ASCO) Annual Meeting. The company presented a series of abstracts that demonstrated the exceptional breadth and depth of their screening and diagnostic portfolio. Of particular significance was the validation of the predictive and prognostic value of the Oncotype DX Breast Recurrence Score, offering new hope for millions of patients worldwide.Exact Sciences presence at the ASCO Annual Meeting 2024 firmly established the company as a key player in the field of early cancer diagno...
Exact Sciences’s Comment on Sales, Marketing and Customers
Exact Sciences Corporation develops and provides cancer screening and diagnostic tests aimed at earlier cancer detection and treatment guidance. Its product portfolio includes Cologuard, Oncotype DX, Cologuard Plus, Oncodetect, and Cancerguard tests. Oncodetect has received Medicare reimbursement for patients with stage II, III, and resectable stage IV colorectal cancer. The company has an exclusive license agreement with Freenome Holdings, Inc. for blood-based colorectal cancer screening. Customers and market participants associated with Exact Sciences include Abbott Laboratories, Badger Merger Sub I, Inc., and Freenome Holdings, Inc.
Sources:
Exact Sciences Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Exact Sciences Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Exact Sciences Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
78.39 %